sp² Magazine boasts readers from the upper echelons of the pharma and Highly-targeted biotech research and development community through to bench scientists. In circulation particular we have a highly targeted circulation to emerging pharma executives which is where a high number of new business opportunities are arising.

In addition to this we continue to provide unrivalled circulation into the European pharmaceutical and small molecule biotechnology sectors. sp² boasts a fully-qualified, highly-targeted circulation of 8518